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The influence of environmental 
and core temperature 
on cyclooxygenase and PGE2 
in healthy humans
Christopher J. Esh1,4, Bryna C. R. Chrismas2, Alexis R. Mauger3, Anissa Cherif1, 
John Molphy1 & Lee Taylor4,5,6,1* 
Whether cyclooxygenase (COX)/prostaglandin E2 (PGE2) thermoregulatory pathways, observed 
in rodents, present in humans? Participants (n = 9) were exposed to three environments; cold 
(20 °C), thermoneutral (30 °C) and hot (40 °C) for 120 min. Core (Tc)/skin temperature and thermal 
perception were recorded every 15 min, with COX/PGE2 concentrations determined at baseline, 60 
and 120 min. Linear mixed models identified differences between and within subjects/conditions. 
Random coefficient models determined relationships between Tc and COX/PGE2. Tc [mean (range)] 
increased in hot [+ 0.8 (0.4–1.2) °C; p < 0.0001; effect size (ES): 2.9], decreased in cold [− 0.5 (− 0.8 to 
− 0.2) °C; p < 0.0001; ES 2.6] and was unchanged in thermoneutral [+ 0.1 (− 0.2 to 0.4) °C; p = 0.3502]. 
A relationship between COX2/PGE2 in cold (p = 0.0012) and cold/thermoneutral [collapsed, condition 
and time (p = 0.0243)] was seen, with higher PGE2 associated with higher Tc. A within condition 
relationship between Tc/PGE2 was observed in thermoneutral (p = 0.0202) and cold/thermoneutral 
[collapsed, condition and time (p = 0.0079)] but not cold (p = 0.0631). The data suggests a thermogenic 
response of the COX/PGE2 pathway insufficient to defend Tc in cold. Further human in vivo research 
which manipulates COX/PGE2 bioavailability and participant acclimation/acclimatization are 
warranted to elucidate the influence of COX/PGE2 on Tc.
Environmental temperature can challenge human homeostasis. Indeed, hot and cold exposures are able to 
elicit favorable (e.g.  hormetic1,2) and  detrimental3,4 acute responses and chronic adaptations. Such exposures 
(natural or artificial) can be extreme in nature (e.g. sauna, ice water immersion, etc.), yet are used increasingly 
in  clinical3,5,6,  health7,8 and athlete performance (e.g. heat acclimation/acclimatization1,9 and  rehabilitation6 
paradigms). Although humans are remarkably tolerant to extremes of temperature through behavioural 
 thermoregulation10,11 and acute/chronic  physiological1,2,  biological12,13 and  psychological14,15 responses/adapta-
tions, if the thermoregulatory challenge becomes too great, changes in core temperature (Tc) of ~  ± 2.5 °C can 
lead to severe and potentially fatal health issues (e.g. heat stroke, cardiac arrhythmias, multi-organ failure, etc.3,4) 
through hypo- and hyper-thermia.
With uncompromised thermoregulation (i.e. without illness or pharmacological compromise) the human 
body will initiate heat gain/loss mechanisms (including behavioural) in an orderly manner in response to dif-
fering  environments16. Vasoconstriction, extra clothing and shivering in response to cold and vasodilation, 
seeking shade/a cool environment and sweating in response to  heat10,17,18. An underlying biochemical mecha-
nism/pathway to Tc regulation has received some attention in recent  literature19–21 but is yet to be extensively 
explored or elucidated experimentally (i.e. biochemical analysis) in  humans22,23. Arachidonic acid oxidation by 
cyclooxygenase (COX) isoforms (COX1 and COX2) produces prostaglandins, including the pyrogenic media-
tor prostaglandin E2 (PGE2)24,25. In an afebrile state the constitutively expressed COX1 ‘housekeeping’ isoform 
appears to be the catalyst for PGE2  upregulation26–28. In afebrile rodents and other mammals there is evidence 
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of a COX1 splice variant, named COX3, being the catalyst for PGE2  upregulation20,21,29. However, in humans the 
messenger RNA (mRNA) of many COX1 (and COX2) splice variants have been sequenced without determina-
tion of any physiological  function30,31. Indeed, it is estimated ~ 50% of human genes generate multiple mRNA 
products, often unproductive targets for  degradation32. Therefore, it would appear that in humans COX1 is the 
afebrile catalyst for prostaglandin synthesis. In response to pathological states (i.e. febrile) the inducible COX 
isoform  (COX224,25) is stated to be the catalyst for PGE2 upregulation in  humans33,34 which also results in ther-
mogenesis and a Tc increase (i.e. fever). There is currently no human data to support an afebrile COX1/PGE2 
thermogenic pathway (i.e. Tc maintenance/increase35) however, a reduction in PGE2 in rodents is synonymous 
with Tc  reduction20,21,36. Following acetaminophen [paracetamol (ACT)] administration, a potent in vivo COX/
PGE2 inhibitor in  humans37 and  rodents20,21,36, a reduction in Tc (up to 3.9 °C) was simultaneous with up to 
96% reductions in PGE2 in afebrile rodents housed below their thermoneutral zone  (TNZ20,21,36); “the TNZ is 
a range of ambient temperature at which temperature regulation is achieved only by control of sensible heat loss, 
i.e., without regulatory changes in metabolic heat production or evaporative heat loss.”38. Although similar ACT 
mediated (dose: 20 mg  kg−1 lean body  mass−1) Tc responses have been observed in humans (reduced Tc by up to 
0.57 °C; a response absent without ACT ingestion) when exposed to conditions below their TNZ [10 and 20 °C 
40% relative humidity (RH)22,23], they were not supplemented by biochemical analysis of COX and PGE2, thus 
this pathways implication remains unclear in  humans31.
The evidence  (rodents20,21,36) and provisional data/discussion  (humans19,22,23) provides a plausible hypothesis 
that the COX/PGE2 pathway may influence Tc regulation in humans. Thus, this study will explore the COX/
PGE2 pathway (COX1, COX2 and PGE2 concentrations) in response to acute exposure to different environmen-
tal conditions (cold, hot and thermoneutral) that challenge or maintain Tc. Indeed, deductive research designs 
have been called  for35 and are thus required to elucidate the influence of COX/PGE2 on human Tc regulation. 
It is hypothesized that rectal temperature (Trec) will: (i) significantly increase in a hot environment; (ii) remain 
stable in a cold (as seen  elsewhere22,23) and (iii) thermoneutral environment. Further, concentrations of COX 
and PGE2 will be implicated in Tc changes, specifically: (iv) COX1 concentrations will decrease (i.e. catalyzed) 
in the cold environment (where Trec will be challenged yet defended and remain stable) and remain stable in the 
thermoneutral (where Trec will remain stable) and hot (where Trec will increase); (v) COX2 will remain stable 
across all conditions in the absence of a febrile stimulus; (vi) PGE2 concentration will increase in the cold but 
remain stable in the thermoneutral and hot environment.
Methods
All study procedures were approved by the Anti-Doping Lab Qatar (ADLQ) Institutional Review Board 
(F2017000234), in the spirit of the Helsinki Declaration and executed within an Orthopaedic and Sports Medi-
cine hospital in accordance with ADLQ guidelines and regulations. Nine healthy males (30 ± 3.0 y, 1.80 ± 0.06 m, 
83.0 ± 6.25 kg, body fat % 19.1 ± 4.56) were recruited and voluntarily signed an informed consent form prior to 
taking part.
A Tc null zone where there is no sweating or shivering has been  observed39 indicating that a ± 0.3 °C change in 
Tc is physiologically meaningful (i.e. the induction of significant heat gain/loss mechanisms). A ≥ 0.3 °C change 
in Tc determined if the environmental conditions significantly disrupted homeostasis. Based on this data a power 
calculation (G*Power Software Version 3.0.10, Henrich University, Dusseldorf, Germany) was performed for 
changes in Tc; a sample size of six was required to achieve a statistical power of 0.90. Nine participants were 
recruited to ensure six full datasets. Normative values or experimental data (including environmental challenges) 
of COX1, COX2 and PGE2 concentrations, from robust experimental designs, are not available in vivo in humans. 
Power calculations were therefore not feasible for bio-chemical outcome measures.
This study employed a randomized repeated measures experimental design with three experimental condi-
tions [Cold (COLD), Thermoneutral (TN) and hot (HOT)] and laboratory visits. The COLD condition was 
determined as ‘cold’, from a thermoregulatory perspective because 20 °C is below the human TNZ therefore, 
heat retention/generation is required to maintain a homeostatic  Tc40. Each trial was separated by at least 48 h.
Experimental controls. Participants did not ingest (confirmed verbally on arrival to each laboratory visit) 
any over-the-counter or prescription drugs in the 48 h prior to testing, thus specifically controlling for the vast 
array of drug formulations [e.g. ACT and non-steroidal anti-inflammatory drugs (NSAID)] that target COX 
isoforms and inhibit the production of prostaglandins in vivo (e.g.  PGE237,41). Additionally, they refrained from 
caffeine intake and exercise in the 24 h prior to testing. Participants arrived at the research laboratory fasted 
overnight between 08:00 and 10:00 a.m.; timing was kept constant following the first visit to avoid any circadian 
influence on Tc between  trials42. Testing only commenced if participants presented with a Tc ≤ 37.5 °C (no par-
ticipants were excluded for a high baseline Tc).
Procedures. Prior to experimental visits body fat % was assessed via dual energy X-ray absorptiometry 
[DEXA (Lunar iDXA, GE Healthcare, Chicago, USA)] conducted and analyzed by the Aspetar radiology depart-
ment. Upon arrival at the research laboratory participants had their height and weight measured (first visit only; 
SECA column scales with telescopic height, Hamburg, Germany) and were instrumented with rectal and skin 
thermistors. Participants were asked to sit for 10 min in the clothes they arrived in to obtain a baseline Tc. They 
entered the environmental chamber (Guangdong Sanwood Technology Corporation, Guangdong, China) where 
a cannula (Vasofix Safety, B Braun, Sheffield, UK) was then inserted and a blood sample taken (for blood sample 
timings see Fig. 1). A standardized meal was then provided [50 g cornflakes (Kellogg’s, Michigan, USA; 42 g 
carbohydrates, 0.5 g fat, 3.5 g protein), 250 mL full fat milk (Baladna, Al Khor, Qatar; 11.3 g carbohydrates, 7.5 g 
fat, 7.5 g protein)]. Once the meal was consumed the 120 min experimental period began.
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Environmental conditions. Participants were exposed to three randomized environmental conditions on 
separate occasions for 120 min (COLD: 20 °C 40% RH; TN: 30 °C 40% RH and HOT: 40 °C 40% RH). Envi-
ronmental temperature was statistically significantly different between conditions (p < 0.001), whilst humidity 
was not (p = 0.438) and within condition environmental conditions presented non-significant minimal variation 
(mean ± standard deviation: COLD: 20.07 ± 0.11 °C, 40.20 ± 0.53% RH; TN: 29.82 ± 0.19 °C, 40.53 ± 0.80% RH; 
HOT: 39.94 ± 0.11 °C, 40.21 ± 0.28% RH). In COLD participants were fully clothed (t-shirt, trousers, jacket and 
socks) for the first hour before they removed their jacket and trousers and remained for the final hour in shorts 
and socks only. In TN and HOT only shorts and socks were worn for the duration.
Rectal and skin temperature. Tc data (due to equipment malfunction Tc data is only available for n = 8) 
was obtained via a rectal thermistor (MRB Rectal Probe, Ellab, Hillerød, Denmark) connected to a medical pre-
cision thermometer (DM852 Thermometer, Ellab, Hillerød, Denmark). Participants self-inserted the rectal ther-
mistor 15 cm beyond the anal sphincter upon arrival. To accurately reflect the deep body temperature measure-
ment site used in this study Trec will be used when referring to Tc data from this  study43. Skin temperature (Tsk) 
was measured via skin thermistors (iButton Hygrochron Temperature/Humidity Logger, Maxim Integrated, San 
Jose, USA) that were placed upon four sites (calf, thigh, chest and  triceps44). Each thermistor recorded separately 
(n = 7 in the COLD due to iButton thermistors malfunctioning, i.e. not recording data). Upon cessation of each 
testing day, the data from each thermistor was downloaded to the ibutton data logger (iButton Hygrochron Tem-
perature/Humidity Logger, Maxim Integrated, San Jose, USA). The  Ramanathan44 formula was used to calculate 
Tsk (for Trec and Tsk data recording timings see Fig. 1).
Thermal perception. Thermal perceptions were recorded (for timings see Fig. 1) via visual analogue scales 
(VAS). Thermal sensation (TS) a scale from 1 to 7 (cold–hot), thermal comfort (TC) on a scale from 1 to 7 (too 
cool–much too warm) and shivering (SHV) on a scale from 1 to 4 (not at all shivering–vigorously shivering).
Blood sampling. Blood samples (for timings see Fig. 1) were obtained via cannulation of the antecubital 
vein. Vacutainer tubes (SST II Advance, BD Vacutainer, Plymouth, UK) were inverted as per manufacturer guid-
ance and left to rest upright for 30 min before samples were spun at 1500×g for 10 min in a centrifuge (Hermle 
Labortechnik GmbH, Wehingen, Germany). Serum supernatant was then isolated, aliquoted and stored at 
− 80 °C until required for analysis.
Biochemical analysis. All biochemical markers (COX1, COX2, PGE2) were analyzed by the lead investiga-
tor via commercially available enzyme linked immunosorbent assays [ELISA (Cloud-Clone, Texas, USA)] and 
measured using a Tecan Sunrise Plate Reader (Tecan Group Ltd, Mannedorf, Switzerland). To minimize inter-
assay variation, samples from each participant were analyzed on the same ELISA plate. Inter-assay coefficient 
of variation (CV) for each marker (COX2: 3.78%, PGE2: 6.21%) was less than those stated by the manufacturer 
[manufacturer stated CV < 10% (intra-assay) and CV < 12% (inter-assay)]. All ELISA analysis was completed 
as per manufacturer instruction and values adjusted for any observed plasma volume changes across  time45. 
Haematocrit concentrations were measured to determine plasma  volume45,46, the percentage change in plasma 
volume was added to or subtracted from the absolute concentration of the biochemical marker.
Statistical analysis. Linear mixed models (IBM-SPSS Statistics for Windows, Version 21, Armonk, NY) 
were used to determine any differences (fixed effects model) and relationships (random coefficient model) 
between and within conditions across time. This type of analysis was preferred as it allows for missing data, and 
can model between-subject  variability47, reveal the existence and size of causal effect  heterogeneity48 and deter-
mine differences between/within  groups49. The most appropriate model was chosen using the smallest Hurvich 
and Tsai’s criterion (AICC) in accordance with the principal of parsimony. Prior to any inferential statistics, 
descriptive statistics were checked for normality using quantile–quantile plots, and deemed acceptable. Normal-
ity and homogeneity of variance of the predicted values and residuals for all variables were checked using scatter 
Figure 1.  Schematic of experimental procedures. Abbreviations: core temperature (Trec); skin temperature 
(Tsk); cyclooxygenase (COX); Prostaglandin E2 (PGE2).
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plots. Relationships between (i) Trec and COX2, (ii) Trec and PGE2 and (iii) COX2 and PGE2 were assessed; 
with (i) all data collapsed (condition and time), (ii) collapsed by condition, (iii) collapsed by time and (iv) within 
condition at each time point. Trec data is only available for 8 participants. Relationships between Trec and COX/
PGE2 were therefore determined within 8 participants. COX/PGE2 relationships were determined using the 
full available dataset (n = 9). Hedges’ g effect size (ES) was calculated and interpreted for differences as ‘trivial’ 
(< 0.20), ‘small’ (0.20–0.59), ‘moderate’ (0.6–1.19), ‘large’ (1.20–1.99) or ‘very large’ (> 2.0). Step-up  Hommel50 
adjusted post-hoc pairwise comparison was calculated for each measure if a significant main effect and/or inter-
action effect was present. Two-tailed statistical significance was accepted at p ≤ 0.05.
Results
All comparisons are to baseline and expressed as delta (Δ) changes. The presence and size of differences and 
relationships from the model were not changed whether the raw or Δ data were used. Some raw data will be 
presented for descriptive purposes. Data will be presented as mean (range) unless stated otherwise.
Core temperature, COX and PGE2 response to environmental temperature. Trec (n = 8; all con-
ditions) increased in HOT [+ 0.8 (0.4–1.2) °C; p < 0.0001; ES: 2.9, ‘very large’] and decreased in COLD [− 0.5 
(− 0.8 to − 0.2) °C; p < 0.0001; ES: 2.6, ‘very large’] and was unchanged in TN [+ 0.1 (− 0.2 to 0.4) °C; p = 0.3502]. 
Figure 2 and Table 1 display all main effects, interactions and ES.
COX1 (n = 9) was unable to be detected in the serum with all values below the minimum sensitivity of the 
ELISA kit (0.225 ng  ml−1). Normative values for serum COX1 in humans are not available in the literature to 
the authors knowledge. COX2 (n = 9, see Fig. 3 and Table 2) decreased in the COLD [− 7.0 (− 16.52 to 3.65) ng 
 ml−1; p = 0.0033; ES: 1.0, ‘moderate’] and TN [− 8.55 (23.65 to − 2.08) ng  ml−1; p = 0.0004; ES: 1.3, ‘large’] but 
was unchanged in HOT (+ 0.58 (− 7.59 to 9.80) ng  ml−1; p = 0.8032). PGE2 (n = 9, see Fig. 3 and Table 2) did not 
change across time in any condition (p = 0.1452). Random coefficient models (see Table 3) identified relation-
ships between COX2 and PGE2 (n = 9) in COLD (p = 0.0012) and COLD/TN [collapsed by condition and time 
(p = 0.0243)]. A within condition relationship between Tc and PGE2 (n = 8) was evident in COLD/TN [collapsed 
by condition and time (p = 0.0079)] but not COLD (p = 0.0631). Higher PGE2 concentrations were associated with 
higher Tc (see Fig. 4, panel H). There was no relationship between COX2 and Tc (n = 8) across all models [HOT 
(p = 0.0986); TNZ (p = 0.5935); COLD (p = 0.5917); COLD/TN collapsed for condition and time (p = 0.0749)].
Skin temperature. Tsk (see Fig. 2 and Table 4) increased in HOT [n = 9, + 6.5 (5.19–7.74) °C; p < 0.0001; ES: 
9.3, ‘very large’] and decreased in COLD [n = 7, − 2.38 (− 3.2 to − 1.75) °C; p < 0.0001; ES: 5.2, ‘very large’] but 
did not change in TN [n = 9, + 0.76 (− 0.65 to 4.3); p = 0.0679].
Thermal perception. Increases in TS (+ 0.67 (0.0–2.0); p = 0.0201; ES: 0.9, ‘moderate’) and TC (+ 0.89 (0.0–
2.0); p = 0.0051; ES: 1.0, ‘moderate’) were observed in HOT (n = 9) and decreases in COLD (n = 9, TS: − 1.11 
(− 2.0 to 0.0); p = 0.0001, ES: 1.4, ‘large’; TC: − 1.0 (− 2.5 to 0.0); p = 0.0017; ES: 1.1, ‘moderate’). There was no 
change in TS [− 0.28 (− 1.0 to 0.0); p = 0.3301] or TC [+ 0.44 (0.0–2.0); p = 0.1586)] observed in the TN (n = 9). 
SHV increased in the COLD (n = 9, + 0.94 (0.0–2.0); p < 0.0001; ES: 1.5, ‘large’). Perceptions of SHV did not 
change from baseline (‘not at all shivering’) in HOT or TN (n = 9, p = 1.0000). For main effects, interactions and 
ES see Table 4.
Discussion
HOT [~ + 0.8 Trec (0.4–1.2) °C; ES: 2.9, ‘very large’] and COLD [~ − 0.5 Trec (− 0.8 to − 0.2) °C; ES 2.6, ‘very 
large’] disrupted Trec homeostasis (i.e. Trec alterations exceeded the stated meaningful change; ± 0.3°C39) at rest 
compared to baseline whilst TN did not [+ 0.1 (− 0.2 to 0.4 °C)]; as hypothesized in HOT [hypothesis (i)] and 
TN (iii) but not COLD (ii). COX1 was not detected at any time point within condition whilst changes in COX2 
were seen in COLD [− 7.0 (− 16.52 to 3.65) ng  ml−1; p = 0.0033; ES: 1.0, ‘moderate’]; rejecting hypothesis (iv) 
and (v) respectively. PGE2 did not change significantly at any time point within condition compared to baseline; 
rejecting hypothesis (vi). Significant relationships between COX2/PGE2 in COLD (p = 0.0012), COX2/PGE2 
Figure 2.  (A–D) Delta Trec response to environment (n = 8). (A) Individual Trec response to a cold 
environment (20 °C 40% RH). (B) Individual Trec response to a temperate environment (30 °C 40% RH). 
(C): Individual Trec response to a hot environment (40 °C 40% RH). (D) Mean (no error bars shown for the 
purposes of clarity) Trec response to all environments. Significant main effect of condition (p < 0.001): +Hot 
vs TN (p < 0.001); ‡Hot vs Cold (p < 0.001); ≠TN vs Cold (p < 0.001). *Significant main effect of time (p = 0.01). 
†Significant condition * time interaction (p < 0.001). Significant interaction between conditions: £Hot vs TN; 
$Hot vs Cold; ¥TN vs Cold. (E–H) Delta Tsk response to Environment. (E) Individual (n = 9) Tsk response to a 
cold environment (20 °C 40% RH). (F) Individual (n = 9) Tsk response to a temperate environment (30 °C 40% 
RH). (G) Individual (n = 7) Tsk response to a hot environment (40 °C 40% RH). NB: statistical model was run 
with and without the visual outlier in the TN condition and there was no change in statistical analysis outcomes. 
(H) Mean (no error bars shown for the purposes of clarity) Tsk response to all environments. Significant 
main effect of condition (p < 0.001): +Hot vs TN (p < 0.001); ‡Hot vs Cold (p < 0.001); ≠TN vs Cold (p < 0.001). 
*Significant main effect of time (p < 0.001). †Significant condition * time interaction (p < 0.001). Significant 
interaction between conditions: $Hot vs Cold; ¥TNZ vs Cold. Symbols are used to denote the ES (e.g. (filled 
square) ‘trivial’, (open square) ‘small’, (filled triangle) ‘moderate’, (filled circle) ‘large’, (open circle) ‘very large’).
◂
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(p = 0.0243) and PGE2/Tc (p = 0.0079) in COLD/TN [(collapsed by condition and time) NB: results from this 
analysis should be tempered given the difference in environmental temperature between conditions] were seen, 
with higher PGE2 concentrations associated with higher Trec compared to baseline, supporting the premise of 
a COX/PGE2 thermogenic pathway as hypothesized here and  elsewhere19,35. The nuances of these biochemical 
responses and changes in Trec regulation will subsequently be discussed.
Given the robust evidence from rodent models [simultaneous reductions in Tc (up to 3.9 °C) and PGE2 
(96%)20,21,36] Trec changes were hypothesized to be underpinned by the COX1/PGE2 biochemical pathway. 
Theoretically, COX1 is expressed constitutively (i.e. in an afebrile state) and performs ‘housekeeping’ functions 
to maintain  homeostasis51,52 thus, would be the catalyst for increases in PGE2 and thus rises in Tc. However, 
COX1 was not detected [despite the high sensitivity (0.225 ng  ml−1) of the ELISA kit employed] and within 
the present design it appears not to behave in the manner inferred in  humans19,35 regarding homeostatic Tc 
control. COX2 is widely accepted as an inducible form of COX and is upregulated in pathological states (i.e. a 
febrile  state33,34). However, local (forearm) COX2 inhibition (celecoxib) has attenuated sweat response during 
exercise under heat stress in healthy (free from pathology/febrile state)  humans53. Further, COX2 mRNA has 
been present in many tissues free from pathology (e.g. lung, liver, kidney,  stomach54–57) but this is not conclusive 
evidence of constitutive COX2 expression; mRNA expression of COX2 does not always guarantee the presence 
of a functional COX2  enzyme57,58. It is generally accepted that in a febrile state it is COX2 that is upregulated (i.e. 
responds to the febrile stimulus) inducing an increase in the pyrogenic mediator PGE2 and subsequently a rise in 
Tc (i.e.  thermogenesis24,25). The current study aimed to identify the central mechanism of Tc regulation by COX/
PGE2. Interestingly, a series of studies has shown that COX/PGE2 may be implicated in peripheral mechanisms 
that may modulate  Tc53,59–61. Indeed, during exercise heat stress (35 °C 20% RH) inducing moderate (400 W) 
metabolic heat production local (forearm) COX inhibition reduced sweating but not cutaneous vasodilation; 
this attenuation of sweating was however lost during a bout of high (700 W) metabolic heat  production53,59. 
Somewhat paradoxically local administration of COX products PGE1, PGE2 and prostacyclin (or PGI2) do not 
appear to influence sweating but do induce cutaneous  vasodilation60,61; although the thermoneutral conditions 
Table 1.  Mean differences in Trec (°C) compared to baseline and between condition interactions. Values 
expressed as mean (range). Raw BL values presented for context. Bold and italic text denotes a significant 
finding. Symbols are used to denote the ES (e.g. ■‘trivial’, □‘small’, ▲‘moderate’, ●‘large’, ○‘very large’).
n = 8 Hot TN Cold Hot vs TN Hot vs cold TN vs cold
BL 36.9 (36.5–37) 36.8 (36.4 to 37.2) 36.9 (36.6 to 37.3)
P value 0.4519 1.0000 0.4519
ES 0.36□ 0.0■ 0.29□
CI (95%) − 0.141 to 0.316 − 0.229 to 0.229 − 0.141 to 0.316
0 0.1 (− 0.1 to 0.8) 0.1 (0.0 to 0.4) − 0.1 (− 0.2 to 0.0)
P value 0.8937 0.0335 0.0461
ES 0.05■ 0.76▲ 1.41●
CI (95%) − 0.17 to 0.2 − 0.38 to − 0.02 − 0.37 to 0.0
15 0.4 (0.2–0.9) 0.1 (− 0.1 to 0.4) − 0.1 (− 0.3 to 0.0)
P value 0.0015  < 0.0001 0.0081
ES 1.24● 2.87○ 1.36●
CI (95%) 0.116–0.484 − 0.73 to − 0.37 − 0.43 to − 0.07
30 0.5 (0.3–0.9) 0.1 (− 0.2 to 0.5) − 0.1 (− 0.3 to 0.0)
P value  < 0.0001  < 0.0001 0.0081
ES 1.75● 4.02○ 1.20●
CI (95%) 0.12–0.48 − 0.86 to − 0.49 − 0.43 to − 0.07
45 0.6 (0.4–0.9) 0.1 (− 0.2 to 0.4) − 0.2 (− 0.4 to 0.0)
P value  < 0.0001  < 0.0001 0.0001
ES 2.66○ 5.25○ 1.63●
CI (95%) 0.34–0.71 − 1.02 to − 0.65 − 0.5 to− 0.13
60 0.7 (0.5–1.0) 0.1 (− 0.2 to 0.4) − 0.3 (− 0.5 to − 0.1)
P value  < 0.0001  < 0.0001  < 0.0001
ES 2.95○ 6.51○ 1.98●
CI (95%) 0.43–0.8 − 1.18 to − 0.82 − 0.57 to − 0.2
75 0.8 (0.6–1.0) 0.1 (− 0.2 to 0.4) − 0.3 (− 0.5 to − 0.1)
P value  < 0.0001  < 0.0001  < 0.0001
ES 3.49○ 6.82○ 2.07○
CI (95%) 0.49–0.86 − 1.28 to − 0.92 − 0.61 to − 0.24
90 0.8 (0.6–1.0) 0.1 (− 0.3 to 0.4) − 0.4 (− 0.6 to − 0.2)
P value  < 0.0001  < 0.0001  < 0.0001
ES 3.25○ 6.81○ 2.00○
CI (95%) 0.49–0.86 − 1.3 to − 0.93 − 0.62 to − 0.25
105 0.8 (0.5–1.1) 0.1 (− 0.2 to 0.4) − 0.4 (− 0.7 to − 0.2)
P value  < 0.0001  < 0.0001  < 0.0001
ES 3.17○ 5.84○ 2.16○
CI (95%) 0.52–0.88 − 1.35 to − 0.98 − 0.65 to − 0.28
120 0.8 (0.4–1.2) 0.1 (− 0.2 to 0.4) − 0.5 (− 0.8 to − 0.2)
P value  < 0.0001  < 0.0001  < 0.0001
ES 2.67○ 5.22○ 2.65○
CI (95%) 0.5–0.87 − 1.45 to − 1.08 − 0.76 to − 0.39
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in these  studies60,61 may account for this superficial paradoxicality relative to other  data53,59. Ultimately, the 
COX/PGE2 pathway is highly complex, likely integrating central and peripheral mechanistic effects to govern 
dynamic whole body thermoregulation. In HOT, COX2/PGE2 concentrations did not change, indicating the 
rise in Trec (all participants in HOT ≥  + 0.3 °C Trec change; indicative of an uncompensable hot environment) 
was not a product of the COX/PGE2 pathway; whether a larger increase in Trec would have seen such a response 
requires further investigation.
COX1 was not detected in this study. However, COX2 significantly decreased in COLD and TN indicating 
catalysis of readily available (i.e. constitutively expressed) COX2 and a thermogenic response (i.e. utilization of 
COX2 inducing upregulation of PGE2 thus heat production and defense of Trec). However, caution must be exer-
cised when interpreting any in vivo molecule/marker in isolation within a host as complex as humans. Indeed, 
solely attributing homeostatic ‘housekeeping’ functions to COX1 and pathophysiological functions to COX2 
oversimplifies the role of these highly complex isoforms in humans and in some instances is wholly  inaccurate33. 
Indeed, it is estimated ~ 50% of human genes generate multiple mRNA products, often unproductive targets 
for  degradation32. COX1 and COX2 oxidize arachidonic acid at different concentrations, > 10 µM and ≤ 2.5 µM 
 respectively62,63. It is likely therefore, that COX1 oxidizes arachidonic acid in the immediate response to patho-
logical stimuli (i.e. the febrile response) where intense activation of phospholipases release a burst of arachidonic 
acid, COX2 only becomes functional as arachidonic acid concentration falls below the threshold of COX1 
 oxidation26. COX2 is inducible across all mammalian  cells64 and when both isoforms are available in the same 
cell, use of exogenous arachidonic acid is via  COX262. At arachidonic acid concentrations between 50 nM and 
1 µM, COX1 produces less than 25% of the ‘product’ of  COX265. Importantly this concentration range is likely 
what is available in vivo and allows COX2 to act independently of  COX164. Furthermore, COX isoforms are 
the rate limiting enzyme for a plethora of prostaglandins [(PGE2, PGD2, PGF2α and PGI2 and thromboxane’s; 
TXA2 and  TXB252]. COX oxidization of arachidonic acid produces the unstable prostaglandin intermediary 
PGG2 that is peroxidized to PGH2; metabolism of this compound via specific enzymatic activities produces the 
required  PG52. The abundance of prostaglandin’s that can be produced from COX oxidation of arachidonic acid 
dictate that the production of PGE2 is not directly related to the concentrations of COX utilized (i.e. one ‘unit’ 
of COX does not produce one ‘unit’ of PGE2). Together, such data may in part, underpin the lack of detectable 
COX1 in the current study.
Nevertheless, the data from COLD and the individual variation in Trec in TN [+ 0.1 (− 0.2 to  + 0.4) °C; ~ 33% 
participants having a change in Trec that exceeded the ≥ 0.3 °C meaningful change in  Trec39] questions whether 
the TN condition was truly thermoneutral for all participants [i.e. changes in metabolic heat production/evapora-
tive heat loss and Trec should not have been observed using the TN environmental conditions (TN: 30 °C 40% 
RH) recommended widely; 28–32°C66–68]. It is plausible given the demographics of the participant’s [residing 
in a hot desert climate (yearly: mean: 28 °C; mean high: 42 °C; mean low: 14 °C) and their regular exercise heat 
stress exposure; such implications are discussed in detail within the next paragraph] generic models of the 
TNZ may not in retrospect be applicable to this cohort. Recent conjecture suggests much individual variation 
(23–26°C40; ~ 26–33°C69) in TNZ boundaries across populations; indeed, one study was not able to distinguish an 
upper critical temperature limit for the TNZ using a dynamic approach (lower limit: ~ 23°C70). However, without 
measurement of skin blood flow (SkBF) to determine changes in vasoconstriction/dilation or the assessment of 
metabolic rate and sweat rate within the present design, absolute certainty regarding these postulations is not 
possible. Therefore, the TN condition may have induced mild cold stress in some of the current cohort although, 
a significant upregulation of PGE2 and increase in Trec (as hypothesized  elsewhere19) did not occur in either 
TN or COLD. However, there was a significant relationship between COX2 and PGE2 in COLD and COLD/
TN (collapsed by condition and time) where higher concentrations of PGE2 were associated with higher Trec 
(see Fig. 4 panel E and H). This data suggests a thermogenic contribution from the COX/PGE2 pathway which 
may however be compromised within the current cohort (discussed in detail in the paragraph below) relative to 
its ability to evoke a thermogenic increase in Trec [seen  elsewhere22,23 in identical conditions (20 °C 40% RH)].
The participant demographic in this study may have significant implications for the interpretation of the 
results. In COLD it was hypothesized that Trec would be defended (i.e. no significant change in Tc), as seen 
elsewhere when participants were exposed to the same (20° C 40% RH) or colder (10 °C) conditions and ther-
mogenic mechanisms were not inhibited (e.g. via pharmaceutical  intervention22,23). The participants in the 
current study resided in a hot climate (Doha, Qatar) and regularly exercised outside. This study took place in 
the summer months (May–July; average temperature 33 °C with peaks of ~ 42 °C) likely resulting in some heat 
acclimatization adaptations, although this study did not quantify this. It is well noted that cold/heat acclimation/
acclimatization elicits a variety of thermoregulatory adaptations in  humans2,14, other  mammals71 and  rodents72. 
Indeed, in response to a 5-h cold exposure (− 5 °C) cold acclimated rat Tc increased (+ 1 °C) yet decreased 
(− 11 °C) when heat  acclimated73. A previous human study utilizing non-heat acclimatized individuals saw Tc 
reduced (up to 0.39 °C) in the same cold conditions as the current study [20 °C 40% RH (by 0.57 °C in 10 °C 
40% RH)] only when ACT was administered (a potent COX inhibitor and hypothermic agent) but remained 
stable in the placebo condition [compared to a maximum − 0.8 °C reduction in Trec in the current study (COLD: 
20 °C 40% RH) without ACT  administration]22,23. In the only human study to date assessing COX2 and PGE2 
changes following a heat acclimation protocol, COX2 (17.3%) and PGE2 (18.5%) concentrations decreased from 
pre to post  acclimation74. Plasma volumes (that are significantly altered in response to heat  acclimation2) were 
not adjusted relative to the ELISA analysis performed within that  study74 and the acclimation protocol only 
involved 10 half-body water immersions (42 °C) of 30 min across 3 weeks; so the data from that  study74 should 
be interpreted with some caution. To further illustrate the effect of heat acclimation/acclimatization status on 
the study specific cold stress response experienced (e.g. the present data compared  to22), identical conditions 
(20 °C 40% RH) were perceived as colder (mean TS score 2.1 = ‘cool’) in the present study compared to previous 
data (mean TS score 3.4 = ‘comfortable’22). Together, these results present a plausible explanation for the heat 
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acclimated rodent response to a cold  exposure73 and the inconsistencies presented between our and previous 
human  data22,23. Finally, air flow is a central component of the conceptual heat balance equation and in the 
present study air flow was minimal (although not recorded) whilst being unreported  elsewhere22,23; future work 
should control and report this variable. The data in the current study [increase in PGE2 = higher Trec in COLD 
and COLD/TN (collapsed by condition and time)] and discussion presented here posit that the COX/PGE2 
pathway may be compromised by heat acclimation/acclimatization, rendering  rodents73 and  humans74 less able 
to defend their Tc in response to cold stress. The lack of biochemical analysis in the previous human  data22,23 
and quantifiable acclimation status in the current study however do not allow definitive conclusions regarding 
these postulations. Therefore, further deductive human research designs comparing heat acclimatized and non-
acclimatized participants are required to explore the above discussions.
The disparity between the human data presented in the current study and rodent models may be due to 
the differences between species (e.g. coverage of hair and body size) which significantly affects how each 
 thermoregulate75,76. For example, humans heavily rely on evaporation for heat loss, particularly during  exercise77, 
whereas rodents easily dissipate heat via passive mechanisms because they have a large surface area to volume 
 ratio76. As discussed previously, acclimation/acclimatization affects thermoregulatory  mechanisms2,14,72; rodents 
used for research are generally housed in environments that are below their  TNZ72,78. Constant exposure to this 
thermal cold stress (i.e. a cold environment below their TNZ) induces compensatory mechanisms/cold accli-
mation (i.e. increases in non-shivering thermogenesis and metabolic  activity72); as seen in the rodent literature 
discussed  above20,21,36. Whether the COX/PGE2 thermogenic pathway exhibited in rodents is therefore a product 
of chronic cold stress requires further deductive investigation. Importantly, the rodent evidence for the COX/
PGE2 pathways influence on thermoregulation is  strong20,36 but not unequivocal. Indeed, recent research has 
cited that inhibition of lipolysis and mitochondrial function could be the cause of the hypothermic actions 
of ACT in afebrile rodents and not the inhibition of COX and  PGE279. The data discussed here highlight it is 
paramount that results from rodent models are not generalized to humans without  investigation31 and further 
in vivo research is required to elucidate the thermoregulatory influence of the COX/PGE2 pathway in humans.
Future work would benefit from addressing the limitations within the present experimental design. Norma-
tive values for COX/PGE2 in any human bodily fluid (e.g. blood, cerebrospinal fluid) would aid in the inter-
pretation of these and future results and determine if blood concentrations reflect those in the brain and can be 
used as a reliable measure of central Tc regulation. Further, there is a need to understand central and peripheral 
COX and PGE2 thermoregulatory mechanisms and identify if sex differences in the response of COX/PGE2 
to environmental temperature exist. Quantifiable measures of shivering, sweating, heart rate and SkBF would 
have been advantageous to understand the thermoregulatory responses and the level of thermal stress elicited 
by the environmental temperatures relative to the TNZ. Additionally, given its major role in thermoregulatory 
responses to extremes of environments either side of the TNZ, acclimation status (both hot and cold) should be 
well-controlled and/or experimentally manipulated within future research designs.
Conclusion
To conclude, there was a significant relationship between COX2 and PGE2 in COLD and COLD/TN (collapsed 
by condition and time) and higher Trec was associated with higher PGE2 concentrations. Further deductive 
research designs are required to elucidate the thermogenic influence of this pathway in humans alongside the 
precise implication of acclimation (hot and cold) on COX/PGE2 concentrations and Tc within this paradigm.
Figure 3.  (A–D) Delta COX2 response to environment (n = 9). (A) Individual COX2 response to a cold 
environment (20 °C 40% RH). (B) Individual COX2 response to a temperate environment (30 °C 40% RH). 
(C) Individual COX2 response to a hot environment (40 °C 40% RH). (D) Mean (no error bars shown for the 
purposes of clarity) COX2 response to all environments. Significant main effect of condition (p = 0.001): +Hot 
vs TN (p < 0.001); ‡Hot vs Cold (p = 0.015). *Significant main effect of time (p < 0.01). †Significant condition * 
time interaction (p = 0.04). +Hot vs TN; ‡Hot vs Cold; ≠TN vs Cold. *Significant main effect of time (p < 0.001). 
†Significant condition * time interaction (p < 0.001). Significant interaction between conditions: £Hot vs TN; 
$Hot vs Cold; ¥TN vs Cold. (E–H) Delta PGE2 response to Environment (n = 9). (E) Individual PGE2 response 
to a cold environment (20 °C 40% RH). (F) Individual PGE2 response to a temperate environment (30 °C 40% 
RH). (G) Individual PGE2 response to a hot environment (40 °C 40% RH). (H) Mean (no error bars shown 
for the purposes of clarity) PGE2 response to all environments. Significant main effect of condition (p = 0.006): 
+Hot vs TN (p = 0.008); ‡Hot vs Cold (p = 0.004). Significant interaction between conditions: £Hot vs TN; $Hot 
vs Cold. Symbols are used to denote the ES (e.g. (filled square) ‘trivial’, (open square) ‘small’, (filled triangle) 
‘moderate’, (filled circle) ‘large’, (open circle) ‘very large’).
◂
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Table 2.  Differences in COX2 and PGE2 concentration compared to baseline and between condition 
interactions. Values expressed as mean (range). Raw BL values presented for context. Bold and italic text 
denotes a significant finding. Symbols are used to denote the ES (e.g. ■‘trivial’, □‘small’, ▲‘moderate’, ●‘large’, 
○‘very large’).
n = 9 Hot TN Cold Hot vs TN Hot vs cold TN vs cold
COX2 (ng/ml)
BL 31.07 (20.44 to 45.66)
38.27 (27.99 to 
68.66)
37.22 (28.15 to 
49.27)
P value 0.2573 0.0571 0.4308
ES 0.55□ 0.78▲ 0.08■
CI (95%) − 14.86 to 0.45 − 14.04 to 1.74 − 6.84 to 8.94
60 − 0.53 (− 51.8 to 6.80)
− 7.45 (− 19.11 to 
− 0.71)
− 2.87 (− 12.82 to 
8.02)
P value 0.0036 0.312 0.0502
ES 1.35● 0.42□ 0.38□
CI (95%) 2.34 to 11.50 − 2.24 to 6.92 − 9.16 to 0.0
120 0.58 (− 7.59 to 9.80) − 8.55 (− 23.65 to − 2.08)
− 7.00 (− 16.52 to 
3.65)
P value 0.0002 0.0015 0.5001
ES 1.36● 1.12● 0.22□
CI (95%) 4.54 to 13.71 2.99–12.16 − 6.14 to 3.03
PGE2 (pg/ml)
BL 9.63 (8.44 to 10.46) 9.00 (8.02 to 9.82) 8.54 (7.29 to 10.02)
P value 0.0736 0.0031 0.1962
ES 0.86▲ 1.15▲ 0.48□
CI (95%) − 0.62 to 1.32 0.383–1.81 − 0.25 to 1.18
60 − 0.02 (− 0.86 to 0.95) 0.21 (− 0.27 to 0.97) 0.31 (− 0.94 to 1.44)
P value 0.3075 0.1528 0.6777
ES 0.48□ 0.51□ 0.16■
CI (95%) − 0.68 to 0.22 − 0.77 to 0.12 − 0.54 to 0.35
120 − 0.6 (− 1.92 to 0.08) 0.18 (− 0.36 to 0.65) 0.20 (− 0.82 to 1.25)
P value 0.0005 0.0003 0.9307
ES 1.54● 1.12● 0.03■
CI (95%) − 1.27 to − 0.38 − 1.29 to − 0.4 − 0.47 to 0.43
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Table 3.  Results from random coefficient model analysis. Results are presented as p values showing the 
significance of each relationship across all conditions (all data collapsed by condition and time), between 
COLD/TN (collapsed by condition and time) and within conditions. Time was included as a factor in 
all models. ES is not presented as this would involve crossover between statistical methods. Significant 
relationships and effects of time are highlighted in bold and italicized.
COX2/Tc (n = 8) PGE2/Tc (n = 8) COX2/PGE2 (n = 9)
Random coefficient Time Random coefficient Time Random coefficient Time
All conditions
P value 0.1585  < 0.0001 0.0730  < 0.0001 0.3437 0.2838
T value 1.492 6.807 2.009 9.479 0.971 1.10
Estimate 0.003 0.12 0.38 0.14 0.01 0.096
CI (95%)  − 0.002 to 0.009 0.08 to 0.15 − 0.004 to 0.08 − 0.11 to 0.17 − 0.01 to 0.03 − 0.09 to 0.28
COLD vs. TN
P value 0.0749 0.9985 0.0079 0.0300 0.0243 0.9468
T value 1.906 0.002 3.03 2.331 2.388 − 0.067
Estimate 0.008 0.00004 0.122 0.09 0.03 − 0.007
CI (95%)  − 0.0009 to 0.17 − 0.04 to 0.04 0.37 to 0.21 0.009 to 0.17 0.003 to 0.05 − 0.23 to 0.21
COLD
P value 0.5917 0.0378 0.0631 0.0372 0.0012 0.1359
T value − 0.550 − 2.313 2.04 − 2.338 8.383 1.606
Estimate − 0.004 − 0.20 0.098 − 0.17 0.10 0.29
CI (95%)  − 0.017 to 0.01 − 0.39 to − 0.01 − 0.006 to 0.20 − 0.33 to − 0.01 0.05 to 0.14 − 0.11 to 0.68
TN
P value 0.5935 0.8256 0.0202 0.8901 0.1625 0.9620
T value 0.547 0.228 3.111 0.144 1.469 − 0.048
Estimate 0.005 0.007 0.17 0.004 0.21 − 0.008
CI (95%)  − 0.16 to 0.03 − 0.06 to 0.08 0.04 to 0.30 − 0.06 to 0.07 − 0.01 to 0.05 − 0.36 to 0.35
HOT
P value 0.0986 0.0985 0.1506 0.0709 0.0619 0.0077
T value − 1.861 1.936 1.560 2.021 − 2.039 − 3.580
Estimate − 0.01 0.095 0.10 0.14 − 0.047 − 0.57
CI (95%)  − 0.31 to 0.003 − 0.02 to 0.21 − 0.44 to 0.25 − 0.01 to 0.30 − 0.09 to 0.003 − 094 to − 0.20
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Figure 4.  Random coefficient models: the relationships across all conditions and the analysis including 
the COLD condition are presented (n = 8). Significance of relationship is detailed in each panel; significant 
relationships are highlighted in bold and italicized. (A) COX2 vs Trec collapsed by condition and time. (B) 
PGE2 vs Trec collapsed by condition and time. (C) COX2 vs PGE2 collapsed by condition and time. (D) 
COX2 vs Trec: COLD and TN collapsed by condition and time. (E) PGE2 vs Trec: COLD and TN collapsed by 
condition and time. (F) COX2 vs PGE2: COLD and TN collapsed by condition and time. (G) COX2 vs Trec: 
COLD collapsed by time. (H) PGE2 vs Trec: COLD collapsed by time. (I) COX2 vs PGE2: COLD collapsed by 
time.
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Table 4.  Mean skin temperature and thermal perception Δ changes across time. Values expressed as mean 
(range). Raw BL values presented for context thermal perceptions (1–7 scale) were only recorded during 
the experimental period (0–120 min)]. Results are presented every 30 min for clarity. Symbols are used to 
denote significant between condition interactions (e.g. *Hot vs TN, #Hot vs Cold, +TN vs Cold) and the ES 
(e.g. ■‘trivial’, □‘small’, ▲‘moderate’, ●‘large’, ○‘very large’). The condition*time column exhibits at what time 
points a significant effect occurred within condition until the significant effect was lost (e.g. Tsk in HOT was 
significantly different from BL from 0–120 min). Significant main effects are highlighted in bold and italicized.
Time (min) Main effects
BL 0 30 60 90 120 Condition Time
Condition * 
time
Tsk (°C) Main effect p < 0.0001 p < 0.0001 p < 0.0001
Hot
n = 9
30.51 (29.88–
31.25)
5.38#○ 
(4.15–6.29)
6.23#○ 
(5.24–7.09)
6.31#○ 
(5.49–7.24)
6.36#○ 
(5.49–7.64)
6.5#○ 
(5.49–7.74)
HOT vs COLD
p < 0.0001
0–120 min
p < 0.0001
TN
n = 9
32.46*● 
(29.14–33.68)
0.14*○ (− 0.25 
to 0.1)
0.5*○ (− 0.75 
to 3.9)
0.73*○ (− 0.15 
to 4.25)
0.7*○ (− 0.45 to 
4.35)
0.76*○ (− 0.65 
to 4.3)
HOT vs TN
p < 0.001 p ≥ 0.0679
Cold
n = 7
30.57+● 
(29.67–31.6)
− 0.08+▲ (− 
0.45 to 0.2)
− 1.82+○ (− 
1.25 to − 2.3)
− 2.13+○ (− 1.4 
to − 2.25)
− 2.37+○ (− 1.6 
to − 3.3)
− 2.38+○ (− 
1.75 to − 3.2)
TN vs COLD
p < 0.0001
15–120 min
p ≤ 0.0016
TS
n = 9 Main effect p < 0.0001 p = 0.4612 p = 0.0022
Hot 5.61#○ (4.0–6.0) 0.44#● (0.0–2.0) 0.67#● (0.0–2.0) 0.61#○ (0.0–2.0) 0.67#○ (0.0–2.0) HOT vs COLDp < 0.0001
60–120 min
p ≤ 0.0201
TN 4.78*
▲ 
(4.0–6.0)
− 0.17*▲ (0.0 
to − 1.0)
− 0.17*● (0.0 
to − 1.0)
− 0.28*● (0.0–
to 1.0)
− 0.28*● (0.0 
to − 1.0)
HOT vs TN
p < 0.0001 p ≥ 0.2428
Cold 3.22
+● 
(3.0–4.0)
− 0.44 (0.0 to 
− 1.0)
− 0.61 (0.0 to 
− 2.0)
− 1.17+● (0.0 
to − 2.0)
− 1.11+● (0.0 
to − 2.0)
TN vs COLD
p < 0.0001
60–120 min
p ≤ 0.0201
TC
n = 9 Main effect p < 0.0001 p = 0.9404 p = 0.0067
Hot 4.94#○ (4.0–6.0) 0.06 (− 0.5 to 1.0)
0.44#▲ 
(0.0–2.0)
0.67#● (− 0.5 
to 2.0) 0.89
#● (0.0–2.0) HOT vs COLDp < 0.0001
90–120 min
p ≤ 0.0350
TN 4.22*
▲ 
(4.0–5.0) 0.33 (0.0–1.0) 0.44 (0.0–1.0) 0.33 (0.0–1.0) 0.44 (0.0–1.0)
HOT vs TN
P = 0.5174 p ≥ 0.1586
Cold 3.0+● (2.0–4.0) − 0.28
+▲ (0.0 
to − 1.5)
− 0.39+▲ (0.0 
to − 1.5)
− 0.78+● (0.0 
to − 2.0)
− 1.0○+● (0.0 
to − 2.5)
TN vs COLD
p < 0.0001
90–120 min
p ≤ 0.0141
SHV
n = 9 Main effect p < 0.0001 p = 0.0006 p < 0.0001
Hot 1.0 (1.0–1.0) 0.0 (0.0–0.0) 0.0#▲ (0.0–0.0) 0.0#● (0.0–0.0) 0.0#○ (0.0–0.0) HOT vs COLDp < 0.0001 p = 1.0000
TN 1.0 (1.0–1.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) HOT vs TNp = 1.0000 p = 1.0000
Cold 1.0 (1.0–1.0) 0.22 (0.0–1.0) 0.44
+▲ 
(0.0–1.0)
0.89+● 
(0.0–2.0) 0.94
+○ (0.0–2.0) TN vs COLDp < 0.0001
45–120 min
p ≤ 0.0074
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